

REMARKS

In response to the Notice of Non-Compliant Amendment, applicants have indicated the correct status of claims 25-29, 34-35, 38-40 and 42-43 as cancelled. Claims 33 and 37 as presented, reflect the amendments made in the 04/06/06 Preliminary Amendment. Applicants have amended claim 13 to correct the dependency.

Restriction Requirement

The Examiner has required applicants to elect a composition or method of use. The Examiner contends that the application contains claims directed to more than one species of the generic inventions, and is required to elect a single species if no generic claim is finally held allowable. The Examiner requires applicants to elect a species of active ingredient if a composition is elected. The Examiner requires applicants to elect a single active ingredient and disease state if method of use is elected.

Applicants elect the composition claims (claims 1-24, 30) with traverse. Applicants elect compound 6-Phenylacetylaminobenzo[b]thiophene-2-carboxylic acid hydroxyamide as the species. Claims 1-3, 6-7, 24 and 30 read on the elected species.

If a telephonic communication with Applicants' representative will aid in the advancement of the prosecution of this application, please telephone the representative indicated below.

Respectfully submitted,

By      /Li Su, Reg. No. 45141/  
Li Su  
Registration No. 45,141  
Attorney for Applicants

Merck & Co., Inc.  
PO Box 2000 - RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-5455

Date: April 15, 2010